Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?
Exelixis (NASDAQ: EXEL) recently reported bad news from a late-stage study evaluating a combination of Cabometyx with Tecentriq in treating liver cancer. The biotech stock immediately sank close to 20%. In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Exelixis stock could be a buy after this clinical setback.
Source Fool.com